Neovascular age-related macular degeneration
Conditions
Interventions
Two groups:1.25mg intravitreal bevacizumab at monthly interval 3 to 6 months versus 2.5mg intravitreal bevacizumab
Sponsors
None listed
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Aged 50 years or older; 2. Subfoveal CNV within the foveal avascular zone due to AMD; 3. Patients with best-corrected visual acuity of better than 1.3 ETDRS logMAR units; 4. Patients physically fit to receive intravitreal injection; 5. Informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Coexisting ocular pathology other than cataract; 2. Media opacities which affect fundus examination or OCT measurements; 3. Previous intraocular surgery except uncomplicated cataract extraction and posterior intraocular lens implantation; 4. Any cataract extraction or laser procedure within 6 months of enrolment; 5. Pregnant patients; 6. Failure to comply with follow up schedule; 7. "Single" eye patients with fellow eye of 20/400 or worse; 8. Verteporfin (Visudyne, Novartis AG, Basel, Switzerland) therapy within 1 month of enrolment in the study eye or 7 days in the fellow eye; 9. Previous anti-VEGF therapy including pegaptanib, bevacizumab and ranibizumab; 10. Previous submacular surgery or external beam radiation therapy; 11. History of fluorescein allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity at 6 month; | — |
Secondary
| Measure | Time frame |
|---|---|
| . Retinal thickness measured by optical coherent tomography (OCT) at each visit ii. Proportion of patients with moderate visual loss at 6 months iii. Proportion of patients with stable or gain in vision at 6 months iv. Intraocular pressure measured by non-contact tonometry (NCT) at each visit v. Changes in macular function as measured by multifocal electroretinography (mfERG) at each visit vi. Changes in fluorescein angiography at 6 months vii. Change in levels of aqueous VEGF, PEDF and other g;1. Retinal thickness measured by optical coherent tomography (OCT) at each visit;2. Proportion of patients with moderate visual loss at 6 months;3. Proportion of patients with stable or gain in vision at 6 months;4. Intraocular pressure measured by non-contact tonometry (NCT) at each visit;5. Changes in macular function as measured by multifocal electroretinography (mfERG) at each visit;6. Changes in fluorescein angiography at 6 months;7. Change in levels of aqueous VEGF, PEDF and other growth factors / cytokines during the study period; | — |
Countries
China
Contacts
Public ContactDr Timothy Y. Y Lai
Outcome results
None listed